<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878615</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr740-18</org_study_id>
    <nct_id>NCT03878615</nct_id>
  </id_info>
  <brief_title>Inflammation and Organ Impact During Hepatic Surgery</brief_title>
  <official_title>Inflammation and Organ Impact During Hepatic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monitoring of inflammatory substances (such as interleukins, CRP, albumine), and markers of
      organ dysfunction (such as creatinine, proenkephaline, amylase, troponine, IFABP and lactate)
      during elective liver resection. The study also includes monitoring of hemodynamic
      parameters, blood loss and postoperative complications. Results are to be used för power
      calculation for future trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During hepatic surgery, blood and urine samples will be obtained at 3 times during surgery,
      at 3 h after resection of liver, at 24 h after resection of liver and at post operative day
      2, and subsequntly analyzed for the above mentioned substances. Routine labs will be
      monitored until patient is discharged from hospital. During surgery, hemodynamic parameters
      will be monitored by Picco calculations. Urine output and blood loss will be registred.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2018</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 2, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemic Intestinal Damage</measure>
    <time_frame>from day of surgery until 24-48 hours postoperatively</time_frame>
    <description>rise in IFABP in nanograms/ml,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney injury</measure>
    <time_frame>from day of surgery and approximately 1 week onwards</time_frame>
    <description>as described by KDIGO (Kidney Disease Improving Global Outcomes) criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal Bacterial Transloction</measure>
    <time_frame>from day of surgery until 24-48 hours postoperatively</time_frame>
    <description>Rise in D-lactate in micromol/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney injury</measure>
    <time_frame>from day of surgery until 24-48 hours postoperatively</time_frame>
    <description>proenkephaline increase in pico mol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney injury</measure>
    <time_frame>from day of surgery until 24-48 hours postoperatively</time_frame>
    <description>NAG units/g increase in urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of Inflammatory Response</measure>
    <time_frame>from day of surgery and approximately 1 week onwards</time_frame>
    <description>Changes in MCP-1, SDF-1, IL-1beta, TNF-alfa, IL-6, IL-8, IL-10 and HMBG-1, in blood samples obtained during and after heptaic surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood loss</measure>
    <time_frame>from day of surgery and approximately 1 week onwards</time_frame>
    <description>need of transfusion</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatic Surgery</condition>
  <arm_group>
    <arm_group_label>Elective Hepatic Surgery</arm_group_label>
    <description>Patientes undergoing elective hepatic resection, managed according to departement routine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>elective surgery, according to deprtement routine</intervention_name>
    <description>none, descriptive study</description>
    <arm_group_label>Elective Hepatic Surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum and urinary samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients scheduled for open liver resection, ASA class I-III.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ASA I-III Patient has given informed consent to participate in study.

        Exclusion Criteria:

        preoperative kidney failure (E-GFR &gt;30), current infection treatment with corticosteroids
        coagulopathy surgical or anatomical conditions that makes patient unsuitable for
        participation (for example reoperation, need of vascular bypass, single tumor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, MD, PhD, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SahlgrenskaUH</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götaland</state>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Ellinor Wisén</investigator_full_name>
    <investigator_title>MD, consultant</investigator_title>
  </responsible_party>
  <keyword>liver surgery</keyword>
  <keyword>hepatic resection</keyword>
  <keyword>inflammation</keyword>
  <keyword>organ dysfunction</keyword>
  <keyword>blood loss</keyword>
  <keyword>IFABP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

